Molecule News and Research

RSS

Rockland produces new Anti-NF-κB monoclonal antibody

Rockland Immunochemicals has produced a new Anti-NF-κB monoclonal antibody validated by several assays relevant for discovery including immunofluorescence microscopy, immunohistochemistry, western blotting and ELISA.

5 May 2011

Physical exercise generates nitric oxide intermediates critical for cardioprotection

Exercise both reduces the risk of a heart attack and protects the heart from injury if a heart attack does occur. For years, doctors have been trying to dissect how this second benefit of exercise works, with the aim of finding ways to protect the heart after a heart attack.

5 May 2011

New MIT drug-delivery nanoparticle could target any type of tumor

MIT chemical engineers have designed a new type of drug-delivery nanoparticle that exploits a trait shared by almost all tumors: They are more acidic than healthy tissues.

4 May 2011

PolyMedix Phase 1B/2 clinical study data presented at ATVB meeting

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that clinical data with PMX-60056 were presented at the American Heart Association's Arteriosclerosis, Thrombosis, and Vascular Biology Meeting in Chicago on April 28, 2011.

4 May 2011

SARcode reports encouraging data from SAR 1118 Phase 2 dry eye trial

SARcode Corporation presented data today for their lead investigational molecule, SAR 1118. In a Phase 2 dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production, and improved visual-related function as compared to placebo. These data were part of the scientific program of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held in Fort Lauderdale, Florida.

4 May 2011

Researchers develop novel spinal cord injury treatment

Rutgers researchers have developed an innovative new treatment that could help minimize nerve damage in spinal cord injuries, promote tissue healing and minimize pain.

4 May 2011

Esperion reports positive results from ETC-1002 Phase 1 study in dyslipidemia

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the results from a Phase 1 study and four preclinical studies for ETC-1002 at the Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions in Chicago.

3 May 2011

Case Western Reserve launches new scientific and computational programs in Ohio

The Case Western Reserve University School of Medicine is pleased to announce it has established the first PhD and MS program in Systems Biology and Bioinformatics in the State of Ohio. Based in the School of Medicine, with the Center for Proteomics and Bioinformatics as its administrative home, the faculty cohort will include faculty from multiple departments and schools, and the fundamental core competencies for this program will include: genes and proteins; bioinformatics; and quantitative analysis and modeling.

3 May 2011

New method helps scientists to determine specific protein molecular structure

The structures of many protein molecules remain unsolved even after experts apply an extensive array of approaches. An international collaboration has led to a new, high-performance method that rapidly determined the structure of protein molecules in several cases where previous methods had failed.

2 May 2011

Bristol-Myers Squibb first quarter net sales increase 5% to $3.3 billion

Bristol-Myers Squibb Company today announced first quarter results that included strong sales and earnings growth, and several key R&D milestones—most notably U.S. regulatory approval for YERVOY. The company also confirmed guidance for the year.

30 Apr 2011

Journal Blood publishes MacroGenics' DART antibody technology preclinical data

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the publication in the journal Blood of preclinical data demonstrating potent inhibition of B-cell lymphoma through redirected T lymphocyte-mediated killing, using its bispecific DART antibody technology.

29 Apr 2011

New PET imaging clinical trial to improve early esophageal, lung cancer detection

Can a simple imaging test help predict the success of cancer treatment, even before the treatment is complete? To begin to answer this question, a new National Cancer Institute-funded clinical trial is using a novel PET imaging technique that could improve the early detection of tumor growth during treatment for esophageal and lung cancer.

29 Apr 2011

FDA accepts OncoMed's IND filing for OMP-18R5 in Phase 1 clinical trial for advanced solid tumors

OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, today announced that the FDA has accepted an IND filing for OMP-18R5, which allows OncoMed to commence Phase 1 clinical testing.

28 Apr 2011

Curis reports first quarter net loss of $6.8 million

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended March 31, 2011.

28 Apr 2011

New discovery in cancer and autoimmune diseases

Researchers in the Faculty of Medicine & Dentistry at the University of Alberta have made an important discovery that provides a new understanding of how our immune system "learns" not to attack our own body, and this could affect the way doctors treat patients with autoimmune diseases and cancer.

28 Apr 2011

Researchers begin approved drugs screening for clinical use against rare diseases

Researchers have begun screening the first definitive collection of thousands of approved drugs for clinical use against rare and neglected diseases. They are hunting for additional uses of the drugs hoping to find off-label therapies, for some of the 6,000 rare diseases that afflict 25 million Americans.

28 Apr 2011

Molecular Partners completes MP0112 phase I/IIa trials in wet AMD, DME

Molecular Partners AG, a leader in the development of next generation therapeutics, announced today that it has completed two phase I/IIa clinical trials with MP0112, its lead molecule targeting VEGF-A.

28 Apr 2011

Scientists weaken long-term memory

Could veterans of war, rape victims and other people who have seen horrific crimes someday have the traumatic memories that haunt them weakened in their brains? In a new study, UCLA life scientists report a discovery that may make the reduction of such memories a reality.

28 Apr 2011

Janssen, Beactica enter drug discovery agreement

Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV.

28 Apr 2011

MIT develops new software to predict complex 3-D DNA structures

While the primary job of DNA in cells is to carry genetic information from one generation to the next, some scientists also see the highly stable and programmable molecule as an ideal building material for nanoscale structures that could be used to deliver drugs, act as biosensors, perform artificial photosynthesis and more.

28 Apr 2011